共 50 条
Impact of Transcatheter Aortic Valve Replacement on Risk Profiles of Surgical Aortic Valve Replacement Patients
被引:5
作者:
Craig, Paige
[1
]
Rogers, Toby
[1
,2
]
Zou, Quan
[1
]
Torguson, Rebecca
[1
]
Okubagzi, Petros G.
[1
]
Ehsan, Afshin
[3
]
Goncalves, John
[4
]
Hahn, Chiwon
[5
]
Bilfinger, Thomas
[6
]
Buchanan, Scott
[7
]
Garrett, Robert
[8
]
Thourani, Vinod H.
[9
]
Corso, Paul
[9
]
Shults, Christian
[9
]
Waksman, Ron
[1
]
机构:
[1] MedStar Washington Hosp Ctr, Sect Intervent Cardiol, Washington, DC 20010 USA
[2] NHLBI, Cardiovasc Branch, Div Intramural Res, NIH, Bldg 10, Bethesda, MD 20892 USA
[3] Miriam Hosp, Div Cardiothorac Surg, Providence, RI 02906 USA
[4] Valley Hosp, Cardiac Surg Program, Ridgewood, NJ USA
[5] Henr Doctors Hosp, Dept Cardiothorac Surg, Richmond, VA USA
[6] Stony Brook Hosp, Dept Surg, Stony Brook, NY USA
[7] Maine Med Ctr, Cardiovasc Serv Line, Portland, ME 04102 USA
[8] St John Hlth Syst, St John Heart Inst Cardiovasc Consultants, St John Clin Cardiovasc Surg, Tulsa, OK USA
[9] MedStar Washington Hosp Ctr, Dept Cardiac Surg, Washington, DC 20010 USA
关键词:
Surgical aortic valve replacement;
Transcatheter aortic valve replacement;
Aortic stenosis;
Bicuspid aortic valve;
DATABASE;
OUTCOMES;
SOCIETY;
UPDATE;
D O I:
10.1016/j.carrev.2020.04.035
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background: The advent of transcatheter aortic valve replacement (TAVR) has changed which patients undergo surgical aortic valve replacement (SAVR). We sought to understand the impact of TAVR on the characteristics of SAVR patients in the United States. Methods: A cohort of 2959 patientswho underwent isolated SAVR at 11 US hospitals that performboth TAVR and SAVR from2013 through 2017were grouped by the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database version (v)2.73 (2011-2014), v2.81 (2014-2017), and v2.9 (2017) to assess temporal trends in patient characteristics. Results: Over time, SAVR patients were younger with fewer preoperative comorbidities. There was a significant decrease in median STS predicted risk of mortality (PROM) score (2.0 vs. 1.8 vs. 1.3, p < 0.001, in v2.73 vs. v2.81 vs. v2.9). Specifically, there were fewer high-risk (STS PROM > 8%: 4.3% vs. 4.7% vs. 1.2%, p = 0.03) and intermediate-risk (STS PROM 4% to 8%: 16.3% vs. 11.7% vs. 4.3%, p < 0.001) patients. The proportion of patients with bicuspid aortic valve disease increased significantly (11.2% vs. 26.9% vs. 36.6%, p < 0.001). Therewere no differences in operative mortality (1.9% vs. 2.1% vs. 1.4%, p = 0.75). Conclusions: The introduction of TAVR has already impacted the demographics, clinical characteristics and risk profiles of patients undergoing SAVR in the US. Now that TAVR is approved for low-risk patients, SAVR is likely to be reserved for younger patients who are willing to receive a mechanical valve and for patients with aortopathy, coronary artery disease, or concomitant mitral or tricuspid pathology. (c) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:959 / 963
页数:5
相关论文
共 50 条